Drugs / Gadoteric acid
Gadoteric acid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT07346131 | Jan → Oct 2026 expected | — | Hôpital Fribourgeois | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02529475 | Feb 2016 → Sep 2020 | Meniere disease | University Hospital, Grenoble | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00447889 | Mar 2006 → Nov 2007 | arterial occlusion | Guerbet | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06731738 Background | Nov 2024 → Nov 2025 | diastolic heart failure | IC TARGETS AS | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gadoteric acid | “Injection protocol 5: gadoteric acid 1 mL/s” NCT07346131 ↗ |
| Known as | Acide gadoterique | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833326 ↗ |
| Known as | Acido gadoterico | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833326 ↗ |
| Known as | Artirem | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833326 ↗ |
| Modality | Diagnostic / imaging agent | “A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP))” NCT06731738 ↗ |
| Route | Intravenous | “will be injected i.v.” NCT06731738 ↗ |